Objective-To characterize the role of a vascular-expressed class 3 semaphorin (semaphorin 3G [Sema3G] Key Words: endothelial cell Ⅲ smooth muscle cell Ⅲ angiogenesis Ⅲ semaphorin Ⅲ neuropilin T he growth of new blood vessels (angiogenesis) is associated with a distinct transition of endothelial cells (ECs) from the quiescent growth-arrested state to an invasive, migratory, and proliferating phenotype. The early steps of the angiogenic cascade are initiated by an intricate interplay between the vascular endothelial growth factor (VEGF) and the VEGF receptor and the Notch and Delta systems to control capillary sprout formation. 1 Invading capillary sprouts eventually anastomose to form a new capillary network that matures by recruiting mural cells to establish directional blood flow. Neuronal guidance molecules (ephrin-Eph, semaphorin-neuropilin (NP)-plexin, netrin-unc, and slit-robo) 2-4 and vessel maturation molecules (angiopoietin/Tie and platelet-derived growth factorplatelet-derived growth factor receptor) 5, 6 have been identified as key regulators of these successive steps. The cross talk between ECs and periendothelial mural cells (pericytes and smooth muscle cells [SMCs]) is particularly important for controlling the activation status of the vascular endothelium. Mural cells are in intimate contact with the maturing EC monolayer to control their quiescent phenotype and their ability to respond to exogenous cytokines, including angiogenic growth factors. 7 Conversely, the loosening of EC/mural cell contacts is an important early step of the angiogenic cascade involving molecules of the transforming growth factor ␤, platelet-derived growth factor-BB, and angiopoietin families of vasculotropic growth factors. 8
T he growth of new blood vessels (angiogenesis) is associated with a distinct transition of endothelial cells (ECs) from the quiescent growth-arrested state to an invasive, migratory, and proliferating phenotype. The early steps of the angiogenic cascade are initiated by an intricate interplay between the vascular endothelial growth factor (VEGF) and the VEGF receptor and the Notch and Delta systems to control capillary sprout formation. 1 Invading capillary sprouts eventually anastomose to form a new capillary network that matures by recruiting mural cells to establish directional blood flow. Neuronal guidance molecules (ephrin-Eph, semaphorin-neuropilin (NP)-plexin, netrin-unc, and slit-robo) [2] [3] [4] and vessel maturation molecules (angiopoietin/Tie and platelet-derived growth factorplatelet-derived growth factor receptor) 5, 6 have been identified as key regulators of these successive steps. The cross talk between ECs and periendothelial mural cells (pericytes and smooth muscle cells [SMCs] ) is particularly important for controlling the activation status of the vascular endothelium. Mural cells are in intimate contact with the maturing EC monolayer to control their quiescent phenotype and their ability to respond to exogenous cytokines, including angiogenic growth factors. 7 Conversely, the loosening of EC/mural cell contacts is an important early step of the angiogenic cascade involving molecules of the transforming growth factor ␤, platelet-derived growth factor-BB, and angiopoietin families of vasculotropic growth factors. 8 Stimulated by the prospect of therapeutically exploiting determinants associated with the angiogenic program, numerous experimental avenues have been pursued to systematically unravel the transcriptome of angiogenic ECs. In the most reductionist approach, the properties of cultured confluent quiescent ECs have been compared with those of subconfluent migrating ECs. 9 Correspondingly, microarray analyses of cultured ECs stimulated by angiogenic cytokines have been pursued. 10, 11 Transcriptomic analyses have also been performed with ECs undergoing capillarylike tube formation in 2D and 3D cellular systems. 12, 13 Correspondingly, several studies have performed transcriptome analyses of angiogenic ECs in vivo. 14, 15 To functionally and molecularly mimic the properties of ECs during angiogenesis, our laboratory has developed a spheroid-based 3D cellular angiogenesis assay. 16 This assay is based on the focal delivery of EC spheroids of defined cell number (between 400 and 1000 cells each) into a gel matrix. ECs sprout focally from the embedded spheroids to establish an anastomosing network of lumenized capillarylike structures. This versatile assay has been adapted for several applications and was also used to establish a novel in vivo angiogenesis assay in which human ECs are grafted as spheroids to establish a complex 3D vasculature in immunodeficient mice. 17 The 3D spheroid-based assay appeared to be a suitable cellular representation of the angiogenic cascade. We exploited it for this reason as a starting point for the systematic transcriptomic analysis of angiogenic ECs. The experiments revealed that the transcriptomic analysis of 3D-sprouting ECs identified a relevant transcriptomic fingerprint of angiogenic ECs, as reflected by the many expected candidate molecules that came up in this screen. The screen has yielded several novel candidate molecules. Class 3 semaphorin (semaphorin 3G [Sema3G]) was 1 of the most promising candidates; and further analyses focused on Sema3G, a novel member of the class 3 family of secreted semaphorins. Class 3 semaphorins are secreted growth factors that act through NP receptors and plexin coreceptors. 18 Unlike the well-characterized class 3 semaphorins, Sema3A through Sema3F, which were identified as neuronal molecules that later exerted functions in the vascular system, Sema3G appears to be a primarily vascular-acting semaphorin.
Methods
Details of the cells and reagents (cell culture, antibodies and reagents), molecular techniques (RNA isolation and microarray processing, analysis of microarray chip data, siRNA selection and transfection of HUVE cells, RT-PCR), protein biochemical techniques (production of recombinant Sema3G, generation of different forms of Sema3G, immunoblot analysis, Sema3G pull-down assay, alkaline phosphatase (AP)-fusion protein binding assay on PAEC), histological techniques (immunofluorescence staining), cellular techniques (3D in vitro angiogenesis assay for transcriptome screening, 3D in vitro angiogenesis assay for target validation, EC-SMC co-culture system, SMC scattering assay, proliferation assay (WST read-out) screen), in vivo techniques (Sema3G deficient mice, knockdown and expression analysis in zebrafish) are summerized in the corresponding supplemental material (available online at http://atvb.ahajournals.org).
Results

Identification of Sema3G by Transcriptomic Profiling of Angiogenic ECs
Transcriptomic profiling of EC (human umbilical vein EC) sprouting for 24 and 48 hours in collagen and fibrin gels (supplemental Figure IA) identified a distinct gene expression profile of angiogenic ECs stimulated with either VEGF or basic fibroblast growth factor (bFGF) (compared with the gene expression profile of unstimulated human umbilical vein ECs cultured as 3D spheroids). A total of 966 distinct probe sets (Affymetrix), corresponding to 784 transcripts, were identified as differentially regulated (Ͼ2-fold change, PϽ0.01) compared with control. Of these sets, 92 transcripts were regulated Ͼ4-fold (63 upregulated and 29 downregulated, supplemental Figure II) . Among the cohort of strongly upregulated genes, 26 (41%) were previously identified as either VEGF-induced genes or implicated in the regulation of angiogenesis (supplemental Figure II) , validating the biological relevance of the experimental approach.
Next, we prioritized 29 genes from the original screening pool of 784 differentially expressed transcripts for further analysis (supplemental Table) . This list of candidate genes was validated in small interfering RNA-based loss-of-function experiments (VEGF-and bFGF-induced 3D spheroid-based sprouting angiogenesis experiments and VEGF-induced proliferation assays, supplemental Table) . Silencing of 4 genes (glia maturation factor ␥, Semaphorin sem2 [Sema3G], SRYbox containing gene 17 (SOX17), and Down syndrome critical region-1) had an inhibitory effect in all tested parameters (supplemental Figure IB and supplemental Table) . Three of these genes (ie, glia maturation factor ␥, SOX17, and Down syndrome critical region-1) have recently been implicated in the regulation of EC function and angiogenesis. 19 -22 Therefore, further analyses focused on the characterization of Semaphorin sem2 (Sema3G) as a novel and differentially expressed EC class 3 semaphorin.
Semaphorins are grouped into 8 classes: 2 invertebrate classes (1 and 2), 5 vertebrate classes (3-7), and 1 viral class (8) . 23 Sema3Gs are the only vertebrate class of secreted semaphorins. Based on structural criteria, sem2 is the seventh member of the Sema3Gs and has consequently been designated as Sema3G. In contrast to the extensively characterized class 3 semaphorins, Sema3A through Sema3F, little is known about Sema3G. 24 -27 Human Sema3G is located on chromosome 3 (3p21.1) and is composed of 16 exons (supplemental Figure VA) . It contains 782 amino acids consisting of a signal sequence, the 446 -amino acid SEMA domain, and an Ig-like domain ( Figure 1A ). The alignment with the other class 3 semaphorins revealed closest sequence homology of Sema3G with Sema3E ( Figure 1B ).
Both the SEMA domain and the Ig-like domain of Sema3G contain putative furin cleavage sites ( Figure 1A ). Recombinant expression consequently yielded 100-kDa full-length Sema3G with (F1) or without myc-tag (F2) and Furin proprotein convertase-processed 65-kDa (F3) and 37-kDa (F4) fragments ( Figure  1C ). Proprotein convertase processing was confirmed by recombinant expression of Sema3G in the presence of a Furin inhibitor that led predominantly to full-length Sema3G production (Figure 1C) . Therefore, 3 mutated forms of Sema3G were generated to study the binding properties and functions of differently processed Sema3G. First, a cleavage-resistant form of Sema3G (Sema3G-Mut) was generated in which both furin cleavage sites were mutated by point mutations ( Figure 1D , lane 3; and supplemental Figure IIIA and supplemental Figure IV) . Next, 2 forms of the completely processed protein (65 kDa) were generated. Sema3G-65oF was fused to a myc tag in a way that the furin cleavage site was removed, yielding a cleavage-resistant tag ( Figure 1D 
Binding Properties of Sema3G
Class 3 semaphorins bind NPs expressed by neuronal and vascular cells. 18 Consequently, we probed Sema3G binding to NPs by performing immunoprecipitation experiments with Sema3G-containing supernatants and NP1-fragment crystallizable region (Fc) or NP2-Fc to pull down bound Sema3G. Western blot analysis using either the S1 antibody (identifying full-length Sema3G [F1] and the processed Sema3G fragments F2 and F3) or myc staining (detecting only full-length unprocessed Sema3G [F1]) confirmed the previously reported binding of Sema3G to NP2 (Figure 2A , S3G-wt). 24 -27 Surprisingly, these experiments revealed that furin proprotein convertase processed Sema domain-containing F2 and F3 Sema3G fragments but not full-length Sema3G (F1) also bound to NP1 (Figure 2A , S3G-wt). In addition, the binding assay was performed for the cloned forms of Sema3G, Sema3G-Mut, Sema3G-65oF, and Sema3G-65F ( Figure 1D and supplemental Figure III and supplemental Figure IV) . Interestingly, the cleavage-resistant form of Sema3G (Sema3G-Mut) strongly bound to NP2 but not to NP1 (Figure 2A , S3G-Mut), whereas the cleaved 65-kDa forms (Sema3G-65oF and Sema3G-65F) did not bind to NP2 or NP1, independently of the exposure of the natural C-terminus (Figure 2A , S3G-65oF and S3G-65F).
To further validate Sema3G binding in a cellular context, we performed a binding assay on porcine aortic ECs overexpressing NP1 or NP2. Sema3G and the control Sema3F were C-terminally fused to alkaline phosphatase (AP). The amount of bound AP was visualized using nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate substrate ( Figure 2B ) and quantified with the soluble substrate p-nitrophenyl phosphate (PNPP) ( Figure 2C ). The assay demonstrated strong binding of full-length wild-type Sema3G to NP2 and weaker binding to NP1. Similarly, Sema3F bound to NP2 and weaker to NP1, as expected, whereas the control-AP yielded no signal.
Expression of Semaphorin3G in Mammalian Tissues
To further explore vascular Sema3G functions, we analyzed the expression of Sema3G in detail by tracing LacZ marker gene expression, which was knocked into the Sema3G locus of mice during the generation of Sema3G-deficient mice (supplemental Methods and supplemental Figure VA and VB). Compatible with the high degree of redundancy of class 3 semaphorin family members, 18 Sema3G-deficient mice were viable and fertile and exhibited no overt vascular morphogenic defects (supplemental Figure VC and VD) . Corresponding data were obtained in zebrafish morpholino gene-silencing experiments, which similarly yielded no overt vascular phenotype. Both a transcriptional start site morpholino and a splice site morpholino did not cause overt defects during zebrafish development (supplemental Figure VI) .
Specific vascular expression of Sema3G was first observed in the fetal aorta around E9.5, spreading to major trunk and brain arteries at E10.5 to E14.5. Sema3G displayed pronounced preferential arterial expression in all organs, which was most evident in the prenatal and postnatal heart, revealing prominent vascular expression in major arteries and branching small arteries ( Figure 3F and supplemental Figure  VII) . To further trace the arterial expression of Sema3G, retinas of 12-day-old Sema3G-null mice were costained for LacZ and the EC and SMC markers Bandeiraea simplicifolia (BS)-1 lectin and ␣-smooth muscle actin (SMA), respectively ( Figure 3A-3D ). Sema3G expression was exclusively detectable in ␣-SMA-costaining arterial vessels. The developmental arterial expression persisted to gradually decline during adolescence, with weak detection after P18 throughout the body ( Figure 3E and supplemental Figure VII) .
LacZ marker tracing indicated that Sema3G was a primarily vascular-expressed class 3 semaphorin. Yet, there were few nonvascular cells expressing Sema3G. These included ␤ Figure 2 . A, Binding of Sema3G to NP1 and NP2 analyzed by pull-down assays. Supernatants of Hek cells stably transfected with the different forms of Sema3G (Sema3G-wt, Sema3G-Mut, Sema3G-65oF, and Sema3G-65F) or control supernatants of mock-transfected Hek cells were incubated with NP1-Fc, NP2-Fc, or control-Fc (Tie2-Fc). Western blot analysis of resulting immunocomplexes using the S1 antiserum showed that NP2 bound full-length Sema3G with myc-tag (F1, *) and the endogenously processed Sema3G fragments (F2, ** and F3, ***). In contrast, NP1 bound the processed Sema3G fragments (F2, ** and F3,***), but did not bind unprocessed full-length Sema3G (F1, *). Cleavage-resistant Sema3G (S3G-Mut) was able to bind to NP2 (F1, *), whereas the cleaved forms (S3G-65oF and S3G-65F) did not bind. The S1 antiserum (left) identified all forms of Sema3G, whereas myc staining identified only full-length unprocessed Sema3G expressing the myc tag at its C-terminus (F1, *). B, Porcine aortic EC (PAEC) expressing human NP1 or NP2 were incubated with conditioned medium containing equal amounts ctr-AP, Sema3G-AP and Sema3F-AP. Binding was visualized with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate. Sema3G bound strongly to NP2 but only weakly to NP1. Sema3F, which was used as control, similarly bound to NP2 and weakly to NP1. The bar indicates 100 m. C, Quantification of the binding assay described in B with the soluble substrate PNPP confirmed the strong binding of Sema3G to NP2 and weak binding to NP1. Results are expressed as meanϮSD of 1 of 3 independent experiments with similar results. *PՅ0.01 vs ctr-AP. Figure VIIIA) and glomerular podocytes in the kidney. 26 Neuronal expression was restricted to dorsal and trigeminal ganglions and the granular layer in the cerebellum (data not shown), confirming the previously observed limited expression of Sema3G in the brain. 27 Cellular RT-PCR analysis of Sema3G indicated expression by several EC populations, including human umbilical vein ECs, human umbilical artery ECs, and human saphenous vein ECs, but not by SMCs ( Figure 4A ). To validate the EC-specific expression of Sema3G in the vessel wall, we performed highresolution double staining of LacZ and ␣-SMA in mouse tissues. These experiments unambiguously confirmed that Sema3G was expressed by ECs and not by SMCs ( Figure 4B) .
cells in the islets of Langerhans of the pancreas (supplemental
Next, we performed a binding assay of Sema3G to SMCs because SMCs in cell culture express the Sema3G receptor NP2 ( Figure 4E ) and might, therefore, be a target cell of secreted Sema3G. Thus, Sema3G, coupled to AP and control AP, was added to SMCs. Quantification of bound AP revealed significant binding of Sema3G to SMCs ( Figure 4C ). The images in Figure 4D also confirmed binding of Sema3G to SMCs. The cellular and in situ expression profiling experiments and the double staining of LacZ and ␣-SMA in mouse tissue clearly showed that Sema3G was not expressed by SMCs. This suggested that Sema3G, which is a secreted protein, bound to and acted on SMCs.
Paracrine Effects of Semaphorin3G on SMCs
The nature of the transcriptomic screening and validation procedure had identified Sema3G as a novel autocrine regulator of EC function (supplemental Figure IB) . Yet, the binding of Sema3G to SMCs in vitro suggested that Sema3G may also exert paracrine functions. Therefore, we pursued cellular experiments to study the effects of Sema3G on EC-SMC interactions and on SMC functions.
To study the effect of Sema3G on EC-SMC interactions, we used a spheroidal EC-SMC coculture system that mimics the 3D assembly of the normal vessel wall. 7 This assay was previously used to assess the vessel destabilizing effects of angiopoietin-2. 8 Recombinant Sema3G, produced in Sf9 cells, was used to stimulate coculture spheroids of ECs and SMCs ( Figure 5A ). Exogenous Sema3G, but not Sema3A used as control, led to rapid and dramatic denudation of the EC monolayer growing on top of a core of SMCs ( Figure  5A ), suggesting a vascular destabilizing effect of Sema3G. To study the direct effects of Sema3G on SMCs, SMC spheroids were embedded in a gel matrix and outgrowth of migrating SMCs into the gel was quantified. Sema3G led to significant SMC outgrowth, similar in efficacy to the effect of bFGF ( Figure 5B ). The effects of Sema3G and bFGF on SMC outgrowth were additive ( Figure 5B ). Sema3A, used as a control, had no effect in this assay.
Next, the SMC migration assay was used to test the effect of the different Sema3G forms on SMC migration. Stimulation with wild-type Sema3G activated outgrowth of SMCs to a similar extent as bFGF, whereas the cleavage-resistant form (Sema3G-Mut) and the completely processed forms of Sema3G (Sema3G-65oF and Sema3G-65F) were not able to induce SMC migration ( Figure 5C ).
Discussion
Several families of neuronal guidance molecules have been identified in recent years to exert guidance and assembly functions in the vascular system. These include ephrins, semaphorins, netrins, and slit molecules. 28 Among the semaphorins, class 3 semaphorins are secreted proteins that are capable of exerting propulsive and repulsive functions by activating their cognate NP and plexin receptors. 23, 29, 30 We report the identification of Sema3G in a differential angiogenic EC transcriptomic screen as a preferentially vascular semaphorin expressed by arterial ECs during vascular development.
Semaphorins 3A through 3F have been extensively studied as propulsive and repulsive path finding molecules controlling neuronal and vascular cells. In contrast, little is known about Sema3G. The first Sema3G publication appeared a few years ago, established the limited expression of Sema3G in the cerebellum, and suggested repulsive neuronal functions. 27 Subsequent studies have shown that the expression of Sema3G may be inversely related to the progression of malignant glioma 24 and that Sema3G may be capable of inhibiting tumor growth in experimental mouse xenograft models. 25 The present study has identified Sema3G as a primarily vascular expressed class 3 semaphorin. Class 3 semaphorins appear to be capable of exerting diverse functions in the vascular system. Secretion by peri-ECs transduces paracrine signaling with repulsive and migration-inhibiting functions on ECs. 31, 32 Repulsive EC functions, translating into a net antiangiogenic outcome, have been best characterized for Sema3A and Sema3F. [33] [34] [35] Sema3A has also been characterized as an autocrine-acting negative regulator of EC integrin activation, thereby exerting antiangiogenic functions. 36 However, class 3 semaphorins have also been reported to elicit attractive cues. [37] [38] [39] Correspondingly, proangiogenic functions of semaphorins have also been described. The membrane-bound Sema4D is capable of exerting proangiogenic effects after proteolytic cleavage. 40 Intriguingly, class 3 semaphorins appear to be able to act context dependently as negative and positive regulators of EC function. For example, full-length Sema3E acts repulsive, whereas proteolytically cleaved Sema3E acts as an attractive guidance cue. 41 Compared with the predominantly repulsive functions of the unraveled class 3 semaphorin functions, Sema3G acts differently in that it positively controls ECs in an autocrine manner and SMCs in a paracrine manner. The mutated uncleaved form of Sema3G was not able to stimulate sprouting, and full processing abolished the biological activity of Sema3G. Thus, only the wild-type Sema3G protein, yielding all cleavage products, acts as the biologically active form of Sema3G.
Mechanistically, the vascular functions of class 3 semaphorins are poorly understood. The original concept that semaphorins act negatively by competing with VEGF for NP binding is not sufficient to explain vascular semaphorin functions. Genetic experiments have provided compelling evidence that NPs act in concert with VEGF to control vascular functions, whereas semaphorins act through NPs and plexins to control neuronal guidance. 42, 43 In turn, plexinD1-deficient mice have an overt vascular phenotype, suggesting direct and rate-limiting semaphorin-mediated effects on vascular patterning. 44 There is also significant phenotypic variation of class 3 semaphorin knockout phenotypes, depending on the genetic background. For example, the vascular phenotype of cluster of differentiation molecule (CD)-1 Sema3A null mice was not observed in a 129/SV or C57/Bl6 background. 36, 45, 46 Similarly, the mortality of Sema3C homozygous mice is Ͻ50% in 129/SV and C57/Bl6 and almost 100% in the CD-1 background. 47 The mild phenotypes of class 3 semaphorin-deficient mice and the phenotypic variation based on genetic background also point toward redundancy mechanisms between different class 3 semaphorins, which are also suggested by their overlapping expression patterns 48 and the observed functional cooperativity. 34 The identification of Sema3G with preferential vascular expression in mammalian tissues adds an additional level of complexity to the analysis of class 3 semaphorin functions. The deletion of Sema3G in mice or zebra fish did not cause obvious morphological or functional defects. Yet, the future generation of mice with targeted deletion of Sema3G and another class 3 semaphorin will likely yield important novel insights into redundancy mechanisms of class 3 semaphorins.
In summary, the present study has led to the identification and initial functional characterization of Sema3G as a preferentially vascular-acting class 3 semaphorin. Sema3G is expressed by angiogenic and developing arterial ECs. It controls ECs in an autocrine manner and SMCs in a paracrine manner. Unlike the previously characterized primarily repulsive and antiangiogenic functions of class 3 semaphorins in the vascular system, Sema3G acts as a positive regulator of angiogenic functions by stimulating ECs and activating Figure 5 . Effect of Sema3G on EC-SMC interactions and on SMC migration. A, Surface CD31 whole mount staining of EC-SMC coculture spheroids treated for 3 hours with Sema3G, Sema3A, or control supernatants (left). Sema3G stimulation, but not Sema3A, led to massive denudation of the surface EC layer, as evidenced by quantification image analysis of the percentage of denuded surface area (right). B, Effect of Sema3G on the migration of SMCs embedded as 3D spheroids into a collagen matrix. Sema3G, but not Sema3A, induced in gel migration of SMCs with similar efficacy as bFGF, which was used as positive control (left). The effect of Sema3G and bFGF was additive (right). *PՅ0.005 vs unstimulated, and **PՅ0.0001 vs unstimulated. C, Only Sema3G-wt induced SMC migration, whereas the other forms of Sema3G (Sema3G-Mut, Sema3G-65oF, and Sema3G-65F) and the control-transfected supernatants were not able to do so. The quantification is on the left. SMCs. Further analysis of this vascular class 3 semaphorin will shed novel light into the biological features of a novel secreted regulator of vascular functions during angiogenesis and may also contribute to the better understanding of the other class 3 semaphorins by shedding light into unrecognized redundancy mechanisms.
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